PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
15.66%
R&D growth while TRVN reduces spending. John Neff would investigate strategic advantage.
40.35%
G&A growth while TRVN reduces overhead. John Neff would investigate operational differences.
No Data
No Data available this quarter, please select a different quarter.
24.17%
Other expenses growth less than half of TRVN's 6728.57%. David Dodd would verify if advantage is sustainable.
22.03%
Operating expenses growth while TRVN reduces costs. John Neff would investigate differences.
22.03%
Total costs growth while TRVN reduces costs. John Neff would investigate differences.
-100.00%
Both companies reducing interest expense. Martin Whitman would check industry trends.
24.17%
D&A growth 1.25-1.5x TRVN's 17.93%. Martin Whitman would scrutinize asset base.
-22.02%
EBITDA decline while TRVN shows 40.94% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-22.03%
Operating income decline while TRVN shows 31.33% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-9.98%
Other expenses reduction while TRVN shows 211.07% growth. Joel Greenblatt would examine advantage.
-22.30%
Pre-tax income decline while TRVN shows 38.72% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
9.98%
Tax expense growth less than half of TRVN's 121.52%. David Dodd would verify if advantage is sustainable.
-22.30%
Net income decline while TRVN shows 38.72% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-22.29%
EPS decline while TRVN shows 40.85% growth. Joel Greenblatt would examine position.
-22.29%
Diluted EPS decline while TRVN shows 38.77% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.